36C24E21Q0017.docx

Contract Opportunity Special Notice

PRODUCT SERVICE CODE

SUBJECT

CONTRACTING OFFICE'S

ZIP-CODE

SOLICITATION NUMBER

ARCHIVE

DAYS AFTER THE RESPONSE DATE

RECOVERY ACT FUNDS

NAICS CODE

CONTRACTING OFFICE

ADDRESS

POINT OF CONTACT

(POC Information Automatically Filled from User Profile Unless Entered)

DESCRIPTION

See Attachment

AGENCY'S URL

URL DESCRIPTION

AGENCY CONTACT'S EMAIL

ADDRESS

EMAIL DESCRIPTION

GENERAL INFORMATION

ADDITIONAL INFORMATION

* = Required Field Contract Opportunity Special Notice

AN23

Intent to sole source 15212-5319 36C24E21Q0017 N 334516 US Department of Veterans Affairs Veterans Health Administration Regional Procurement Office (RPO) East 323 North Shore Drive, Suite 500 Pittsburgh PA 15212-5319 lynn.portman@va.gov The Department of Veterans Affairs, Tennessee Valley Healthcare System, intends to negotiate on a sole source basis, pursuant to FAR 6.302-1, with Nimble Therapeutics for Array Design, Standard Data Processing, and Basic Data Analysis, Six (6) Array Synthesis (custom synthesis), Standard pMHC-I Array Processing, Standard pMHC-I Array Processing (HLA-B*07:02), Standard pMHC-I Array Processing (HLA-B*35:01). Nimble Therapeutics recently developed a proprietary technology that manufactures high density microarrays of antigens—chemicals produced by viruses, such as the flu virus and the SARS-CoV-2, and bacteria such as the pneumonia-causing, anthrax-causing, and tuberculosis causing bacteria. These microarrays are used to probe immune responses of people that have an infectious disease, such as COVID-19 or flu. The identification of antigens informs which are best to make vaccines with. In a similar manner, we will uses Nimble Therapeutics proprietary technology to probe for antigens made by the bacterium that causes tuberculosis. accines are the best way to bring down the health burden caused by tuberculosis in our Veterans. Hence, Nimble Therapeutics has the required advanced technology for high-throughput, reliable, and precise discovery of antigens that will quickly, in one-step, inform on best antigens for anti-tuberculosis vaccine development. This is a notice of intent is not a request for competitive proposals; however, any responsible source who believes it is capable of meeting the requirement may submit a capability statement to the contracting office no later than Monday, November 30th, 12:00, EST. Interest/capability statements may be sent to Lynn Portman at lynn.portman@va.gov. No telephone responses will be accepted. A determination not to compete the proposed requirement based upon the responses to this notice is solely within the discretion of the Government.